drugset
Drugs / Fluzone Quadrivalent vaccine
last change Dec 2020 re-read 9 days ago

Fluzone Quadrivalent vaccine

also known as Fluzone Quadrivalent · Fluzone Quadrivalent, No Preservative

Vaccine

Developed for
influenza
Investigated by
Sanofi Pasteur, a Sanofi Company · National Institute of Allergy and Infectious Diseases (NIAID) · Stanford University

Trials 6

today NCT04551677 · Ph 4 NCT04109222 · Ph 4 NCT03617523 · Ph 4 NCT03308825 · Ph 4 NCT02258334 · Ph 4 NCT03088904 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03088904 Oct 2014 → Dec 2018 influenza Stanford University Completed No outcome recorded
Phase 45 trials
Phase 4 NCT04551677 Sep → Dec 2020 — Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 4 NCT04109222 Sep → Dec 2019 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 4 NCT03617523 Sep → Nov 2018 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 4 NCT03308825 Sep → Nov 2017 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 4 NCT02258334 Oct → Nov 2014 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Fluzone Quadrivalent vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04109222 ↗
5

NCT03088904 ↗

NCT04551677 ↗

NCT02258334 ↗

NCT03308825 ↗

NCT03617523 ↗
Known as Fluzone Quadrivalent “Fluzone® Quadrivalent” NCT04551677 ↗
Known as Fluzone Quadrivalent, No Preservative “Fluzone® Quadrivalent, No Preservative” NCT04109222 ↗
Modality Vaccine “IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.” NCT03088904 ↗
Route Intramuscular “0.5 mL, Intramuscular” NCT02258334 ↗